Soranib (200 mg)

CIPLA LTD. (INDIA)

“Soranib” contains the Drug / Molecule called “Sorafenib”. Sorafenib is a small molecular inhibitor of several tyrosine protein kinases. Soranib treatment induces catabolic mechanism that involve cell degradation; which may suppress tumor growth.

Category:

Indication

Soranib is used for the treatment of Primary Kidney Cancer (Advanced Renal Cell Carcinoma) and Advanced Primary Liver Cancer.

DOSAGE AND ADMINISTRATION:

Recommended daily dose is 400 mg (2 X 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).

Note

SIDE EFFECT :

  • Most commonly occurring Cardiac Ischemia, infarction, Hemorrhage, Hypertension, Hand-Foot skin reaction and rash, Gastrointestinal perforation, Wound healing complications.

INTERACTIONS :

  • Interaction with Docetaxel & Doxorubicin : Soranib can cause increase in plasma concentration of Docetaxel & Doxorubicin

OVERDOSE :

  • There is no specific treatment for Soranib overdose. In cases of suspected overdose soranib should be withheld and supportive care instituted.

Precaution

  • Soranib is a prescription drug and should be used under proper medical guidance and advice.
  • Caution has to be taken in case of kidney / liver problems, pregnancy and lactation.

Related products